RxDoctor Payments Data

Daniel Boone, MD

Internal Medicine · Evans, GANPI 1225131998

Payments from drug & device makers

$15,172in general payments, 2019–2025

Across 1,054 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$854
  • GSK$821
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$15,06099%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,172 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$206,698
Medicare patients
711
Services billed
6,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide360$446,753
EliquisApixaban248$228,684
MounjaroTirzepatide134$166,339
JardianceEmpagliflozin122$154,809
FarxigaDapagliflozin Propanediol155$146,954
TrulicityDulaglutide73$104,940
MyrbetriqMirabegron96$67,954
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$32,481
LinzessLinaclotide28$29,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$27,623
XareltoRivaroxaban30$26,181
JanuviaSitagliptin Phosphate28$25,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$24,665
Breo ElliptaFluticasone/Vilanterol39$23,026
Repatha SureclickEvolocumab32$22,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,434$446,753360 claims
Lilly USA, LLCMounjaro, Trulicity$854$271,279207 claims
PfizerEliquis$331$228,684248 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,263$163,092168 claims
Boehringer IngelheimJardiance$718$154,809122 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$821$75,314114 claims
Astellas Pharma US IncMyrbetriq$345$67,95496 claims
AbbVieLinzess, Synthroid$1,225$40,935156 claims
Johnson & JohnsonXarelto$452$26,18130 claims
MerckJanuvia$342$25,59628 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$448$12,62418 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$327$11,40013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →